Page 2 - Lymphoma Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Despite concerns about the development of secondary T-cell malignancies due to CAR T-cell immunotherapy, experts still believed that the benefits outweigh the risks.

Jonathon B. Cohen, MD, MS, expands on updated data from the BRUIN trial of pirtobrutinib in patients with relapsed BTK-exposed mantle cell lymphoma.

The development of any type of second cancer following CAR T cell therapy is a rare occurrence, as found in an analysis of more than 400 patients treated at Penn Medicine, researchers from the Perelman School of Medicine at the University of Pennsylvania reported today in Nature Medicine.

<p><strong>PHILADELPHIA &ndash; </strong>The development of any type of second cancer following CAR T cell therapy is a rare occurrence, as found in an analysis of more than 400 patients treated at Penn Medicine, researchers from the Perelman School of Medicine at the University of Pennsylvania reported today in <a href="https://www.nature.com/articles/s41591-024-02826-w"><em>Nature Medicine</em></a>. The team also described a single case of an incidental T cell lymphoma that did not express the CAR gene and was found in the lymph node of...

Joanna M. Rhodes, MD, MSCE, discusses the safety and efficacy of treatment with pirtobrutinib following exposure to a covalent BTK inhibitor in heavily pretreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.